New Delhi, Mar 21: Eris Lifesciences Limited announced the acquisition of the prescription probiotics business of Velbiom Probiotics Pvt. Ltd. for a consideration of Rs. 50 crore. This strategic move strengthens Eris’ franchises in Metabolic Wellness and Women’s Healthcare.
Business and Brand Overview
Velbiom is a science-driven bio-therapeutics company committed to the advancement of India-specific microbiome based therapy and research. It is India’s first exclusive probiotic company with a wide range of disease specific, strain specific and site-specific probiotic formulations.
Key brands acquired as part of the deal:
- Lactogut — Multi-strain gastrointestinal health formulation
- Lactogut UG —Recurrent UTI/ Urogenital Wellness in Women
- Lactovit — Daily gut wellness and immune support
Commenting on the deal, Mr. Amit Bakshi, CMD, Eris Lifesciences Limited said
“Prebiotics/ Probiotics represent a fast-growing and high-potential adjacency to our core diabetes and cardio-metabolic franchises. The clinical synergies between GLP-1 therapies and gut microbiome health create a compelling opportunity for Eris to differentiate its disease management proposition.”
